Active Ingredient History
Abemaciclib, previously known as LY2835219, is a potent and selective inhibitor of cyclin-dependent kinases: CDK4 and CDK6, developed by Eli Lilly, which is in clinical trial phase III for the treatment of breast cancer and non-small cell lung cancer (NSCLC) and in phase II for investigation of its treatment glioblastoma and melanoma. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abiraterone Acetate (Phase 3)
Adenocarcinoma (Phase 2)
Adolescent (Phase 2)
Androgens (Phase 3)
Antineoplastic Agents (Phase 3)
Antineoplastic Agents, Hormonal (Phase 3)
Biliary Tract Neoplasms (Phase 2)
Brain Diseases (Phase 1/Phase 2)
Brain Neoplasms (Phase 2)
Breast Diseases (Phase 1/Phase 2)
Breast Neoplasms, Male (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Adenoid Cystic (Phase 1/Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Central Nervous System Diseases (Phase 1/Phase 2)
Central Nervous System Neoplasms (Phase 1/Phase 2)
Child (Phase 2)
Cholangiocarcinoma (Phase 2)
Chondrosarcoma (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Cyclin-Dependent Kinase 4 (Phase 3)
Cyclin-Dependent Kinase 6 (Phase 3)
Cytochrome P-450 Enzyme System (Phase 3)
Diffuse Intrinsic Pontine Glioma (Phase 1)
Endometrial Neoplasms (Phase 2)
Enzyme Inhibitors (Phase 3)
Esophageal Diseases (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fibrocystic Breast Disease (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hepatic Insufficiency (Phase 1)
Hormones (Phase 3)
Liposarcoma (Phase 3)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1)
Lymphoma, Mantle-Cell (Phase 2)
Melanoma (Phase 2)
Meningioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Mutation (Phase 2)
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 2)
Neoplasms by Site (Phase 1/Phase 2)
Neuroblastoma (Phase 1)
Neuroendocrine Tumors (Phase 2)
Neurofibromatosis 1 (Phase 1/Phase 2)
Oligodendroglioma (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Physiological Effects of Drugs (Phase 3)
Prednisolone (Phase 3)
Prednisone (Phase 3)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 3)
Proto-Oncogene Proteins B-raf (Phase 2)
Rhabdoid Tumor (Phase 1)
Rhabdomyosarcoma (Phase 1)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Kaposi (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Steroid Synthesis Inhibitors (Phase 3)
Thyroid Carcinoma, Anaplastic (Phase 2)
Thyroid Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Early Phase 1)
Urogenital Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
